Royalty Pharma (NASDAQ:RPRX) Coverage Initiated by Analysts at Morgan Stanley
Investment analysts at Morgan Stanley began coverage on shares of Royalty Pharma (NASDAQ:RPRX – Get Free Report) in a research note issued on Friday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $51.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 49.91% from the […]
Investment analysts at Morgan Stanley began coverage on shares of Royalty Pharma (NASDAQ:RPRX – Get Free Report) in a research note issued on Friday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $51.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 49.91% from the […]
